Saturday 17 October 2026
Export NNNN’s income statement to Excel — free account
Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
3.29
0.01
−0.30%
Follow NNNN
| Dec '25 | Jun '25 | Dec '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| 0.00% | — | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | — | — | — | |
Free Cash Flow |
0.69 | — | — | — | |
Capital Expenditures |
0.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
1.64% | 0.00% | 0.00% | 0.00% | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | — | — | |
Depreciation/Fixed assets |
0.00 | — | — | — | |
Capex/Depreciation |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | — | — | — | |
Capex per Share |
0.00 | — | — | — | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates